sVE-cadherin and sCD146 serum levels in patients with multiple myeloma.
The role of angiogenesis in multiple myeloma (MM) pathogenesis is well established. Angiogenesis is linked to the functional state of endothelial junctions that are modulated by the growth and activation of endothelial cells. CD146 and vascular endothelial-cadherin (VE-cadherin) are cell adhesion molecules localized at the endothelial junction. The aim of the study was to assess sVE-cadherin and sCD146 serum levels in MM patients. Forty-six untreated patients with MM were included in this study. In addition, 23 of 46 patients were analyzed again in partial remission after initial chemotherapy. Twenty-two samples from healthy volunteers were evaluated as the control. There was no significant difference in sCD146 level between MM patients and the control (511 +/- 177.2 vs. 460.9 +/- 156.9 ng/ml respectively). In untreated MM patients, sVE-cadherin level was significantly higher than in the control (1.36 +/- 0.55 vs. 0.63 +/- 0.56 ng/ml respectively; P < 0.05). In untreated MM patients, sVE-cadherin level was significantly higher than in MM patients in partial remission (1.36 +/- 0.55 vs. 0.5 +/- 0.33 respectively; P < 0.05). sVE-cadherin but not sCD146 serum level was increased in untreated MM patients and decreases after chemotherapy in patients in partial remission. VE-cadherin may reflect intensity of angiogenesis in MM and may be useful in prognosis of response to treatment.
Wrobel
T
T
Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland. wrobelt@hemat.am.wroc.pl
Mazur
G
G
Wolowiec
D
D
Jazwiec
B
B
Sowinska
E
E
Kuliczkowski
K
K
D000368:Aged; D015703:Antigens, CD / Q000097:blood*; D014408:Biomarkers, Tumor; D051929:CD146 Antigen / Q000097:blood; D015820:Cadherins / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000097:blood* / Q000188:drug therapy; D011237:Predictive Value of Tests; D011379:Prognosis; D012074:Remission Induction; D000099152:Cadherin 5
D015703:Antigens, CD; D014408:Biomarkers, Tumor; D051929:CD146 Antigen; D015820:Cadherins; D000099152:Cadherin 5; C497902:MCAM protein, human